Beximco and Mylan’s licensing deal for biosimilar in Bangladesh
Posted on28 Feb 2020
TagsBeximco Pharmaceuticals, licensing deal in pharma, Mylan, mylan licensing deal, Ogivri, trastuzumab
Comments0
Under the terms of the agreement, Beximco Pharma will receive the exclusive rights to launch Mylan’s portfolio of key monoclonal antibodies to... Read More
Health Canada approves Biocon and Mylan’s trastuzumab biosimilar ‘Ogivri’ for HER2-positive cancers
Biocon and Mylan have received the clearance from Health Canada for the latter’s biosimilar Herceptin: trastuzumab co-developed under the brand name Ogivri... Read More